If you have been diagnosed with chronic non-bacterial prostatitis / chronic pelvic pain syndrome (CP/CPPS) and are researching natural health products available in Canada, you will likely encounter two licensed options: Pro-UROL by Aleaf Labs and Urolo-Q by Searchlight Pharma. Both products hold Health Canada NPNs and are formulated around the same two active ingredients — quercetin and rye pollen extract — supported by the same foundational clinical trials.
This article provides a straightforward, evidence-based comparison of both products to help you and your healthcare provider make an informed decision.
Both Products: What They Have in Common
Pro-UROL and Urolo-Q share the same clinical foundation. Both are:
- Licensed by Health Canada as Natural Health Products with active NPNs
- Formulated with quercetin and rye pollen extract as the primary active ingredients
- Authorized for symptomatic support of CP/CPPS
- Based on the same two pivotal clinical trials: Shoskes et al. (1999) for quercetin and Wagenlehner et al. (2009) for pollen extract
- Available without a prescription
Head-to-Head Comparison
| Feature | Pro-UROL (Aleaf Labs) | Urolo-Q (Searchlight Pharma) |
|---|---|---|
| Health Canada NPN | ✓ NPN 80147704 | ✓ NPN 80039114 |
| CP/CPPS authorized indication | ✓ Authorized | ✓ Authorized |
| Active ingredients | Quercetin, Rye Pollen Extract, Bromelain, Papain | Quercetin, Pollen Extract |
| Bioavailability enhancers | ✓ Bromelain + Papain included | Not included |
| Individual ingredient doses disclosed | ✓ Fully disclosed on label | Not fully disclosed |
| Defined treatment course | ✓ 90-day course (Health Canada authorized) | Ongoing daily use |
| Tablets per bottle | 90 tablets | 60 tablets |
| Dosing | 1 tablet, 3x daily with food | 1 tablet, 2x daily |
| Manufacturer location | Canadian-made, GMP certified | Canadian distributor, manufacture origin not disclosed |
| Time-release formula | Standard release | ✓ Time-release |
| Clinical white paper available | ✓ Publicly available | Not publicly available |
The Bromelain + Papain Difference
The most clinically significant formulation difference between Pro-UROL and Urolo-Q is the inclusion of bromelain and papain in Pro-UROL. This is not a cosmetic addition — it has a direct evidence basis.
In the original Shoskes quercetin trial, a subsequent open-label extension tested a formulation combining quercetin with bromelain and papain (the Prosta-Q formula). The responder rate increased from 67% to 82% compared to quercetin alone — a meaningful jump attributable to the proteolytic enzymes enhancing quercetin’s intestinal absorption and bioavailability.
Bromelain and papain are well-characterized proteolytic enzymes that improve the absorption of polyphenolic compounds including quercetin by reducing first-pass metabolism and increasing intestinal permeability to flavonoid molecules. Including them in the same tablet means more quercetin reaches systemic circulation and, by extension, prostatic tissue.
🔗 PubMed: Shoskes et al. — Quercetin + Bromelain/Papain Extension (Urology 1999)Dose Transparency
Pro-UROL discloses the exact quantity of every medicinal ingredient on the label, as required under Health Canada’s NPN licensing conditions. Urolo-Q’s publicly available product information does not disclose the individual quantities of quercetin and pollen extract in each tablet.
Dose transparency matters for two reasons. First, it allows patients and prescribers to assess whether ingredient quantities align with the doses used in positive clinical trials. Second, it is a marker of manufacturing confidence — companies that disclose doses stand behind the consistency of their formulation.
The 90-Day Treatment Course
Pro-UROL is specifically structured as a 90-day treatment course — three tablets daily for 90 days — which aligns with the treatment durations used in the most rigorously conducted clinical trials of rye pollen extract and quercetin in CP/CPPS. Health Canada has authorized this course duration as part of the NPN 80147704 licence.
Urolo-Q is positioned as an ongoing daily supplement without a defined treatment course. While long-term use of these ingredients is generally considered safe, the clinical evidence for CP/CPPS is strongest at 12–24 weeks — not indefinite maintenance. A defined course also creates a clear endpoint for assessing treatment response, which is clinically useful for both patients and their physicians.
The Brachytherapy Trial: New Evidence for the Pro-UROL Formula
Phase 2 RCT — Huntsman Cancer Institute, University of Utah (NCT04252625)
A Phase 2 double-blind, placebo-controlled randomized trial conducted at Huntsman Cancer Institute evaluated the Q-Urol formula — a combination of quercetin, rye pollen extract, bromelain, and papain, which is the same four-ingredient combination present in Pro-UROL — in men with localized prostate cancer following brachytherapy.
Rationale: Brachytherapy commonly induces radiation-related prostatitis symptoms that closely mirror CP/CPPS — pelvic pain, urinary urgency, dysuria, and reduced quality of life. The trial assessed whether the quercetin + pollen + bromelain + papain combination could reduce prostatitis symptom severity in this population over 6 weeks.
Design: Men were randomized 1:1 to receive two capsules twice daily of the active formula vs. placebo. NIH-CPSI-equivalent questionnaires were administered pre- and post-treatment to assess symptom change and quality-of-life impact.
Significance: This trial represents the first prospective RCT evaluating the full four-ingredient combination (quercetin + pollen extract + bromelain + papain) — the same combination in Pro-UROL — in a controlled clinical setting. While conducted in a radiation-induced prostatitis population rather than idiopathic CP/CPPS, the symptom profile and biological mechanisms are directly comparable.
🔗 ClinicalTrials.gov: NCT04252625 — Huntsman Cancer Institute Brachytherapy TrialWhich Product Is Right for You?
Both Pro-UROL and Urolo-Q are legitimate, Health Canada-licensed options for men with CP/CPPS. The choice between them comes down to several practical considerations:
- If bioavailability optimization matters to you: Pro-UROL includes bromelain and papain, which the clinical evidence suggests increases quercetin’s responder rate from 67% to 82%.
- If dose transparency matters to you: Pro-UROL fully discloses all ingredient quantities.
- If a defined treatment course matters to you: Pro-UROL’s 90-day course aligns with the clinical trial evidence and provides a clear framework for assessing your response.
- If time-release delivery is a priority: Urolo-Q offers a time-release formulation, which may suit men who prefer twice-daily dosing over three-times-daily.
We encourage you to discuss both options with your urologist or family physician. The most important decision is committing to a full treatment course with whichever product you choose — the clinical evidence consistently shows that benefit accumulates over 8–12 weeks and early discontinuation is the most common reason for treatment failure.